Svetlana E. Semina

Svetlana E. Semina

Auto-generated profile, based on publicly available information

Svetlana E. Semina

Department of Physiology and Biophysics, University of Illinois Chicago, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2020 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
IKIrida Kastrati
Irida Kastrati
SJStacey E. P. Joosten
Stacey E. P. Joosten
SSSvetlana E. Semina
Svetlana E. Semina
LALuis H. Alejo
Luis H. Alejo
SBSvitlana D. Brovkovych
Svitlana D. Brovkovych
JFJonna Frasor
Jonna Frasor
The purpose of this study was to identify critical pathways promoting survival of tamoxifen-tolerant, estrogen receptor α positive (ER+) breast cancer cells, which contribute to therapy resistance and disease recurrence. Gene expression profiling and pathway analysis were performed in ER+ breast tumors of patients before and after neoadjuvant tamoxifen treatment and demonstrated activation of the NF-κB pathway and an enrichment of epithelial-to mesenchymal transition (EMT)/stemness features. Exposure of ER+ breast cancer cell lines to tamoxifen, in vitro and in vivo, gives rise to a tamoxifen-tolerant population with similar NF-κB activity and EMT/stemness characteristics. Small-molecule inhibitors and CRISPR/Cas9 knockout were used to assess the role of the NF-κB pathway and demonstrated that survival of tamoxifen-tolerant cells requires NF-κB activity. Moreover, this pathway was essential for tumor recurrence following tamoxifen withdrawal. These findings establish that elevated NF-κB activity is observed in breast cancer cell lines under selective pressure with tamoxifen in vitro and in vivo, as well as in patient tumors treated with neoadjuvant tamoxifen therapy. This pathway is essential for survival and regrowth of tamoxifen-tolerant cells, and, as such, NF-κB inhibition offers a promising approach to prevent recurrence of ER+ tumors following tamoxifen exposure.Implications: Understanding initial changes that enable survival of tamoxifen-tolerant cells, as mediated by NF-κB pathway, may translate into therapeutic interventions to prevent resistance and relapse, which remain major causes of breast cancer lethality.

12 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
PPPurab Pal
Purab Pal
AMAlec Millner
Alec Millner
SSSvetlana E. Semina
Svetlana E. Semina
RHRosemary J. Huggins
Rosemary J. Huggins
LRLogan Running
Logan Running
JFJonna Frasor
Jonna Frasor
ET resistance is a critical problem for estrogen receptor-positive (ER+) breast cancer. In this study, we have investigated how alterations in sphingolipids promote cell survival in ET-resistant breast cancer. We have performed LC-MS-based targeted sphingolipidomics of tamoxifen-sensitive and -resistant MCF-7 breast cancer cell lines. Follow-up studies included treatments of cell lines and patient-derived xenograft organoids (PDxO) with small molecule inhibitors; cytometric analyses to measure cell death, proliferation, and apoptosis; siRNA-mediated knockdown; RT-qPCR and Western blot for gene and protein expression; targeted lipid analysis; and lipid addback experiments. We found that tamoxifen-resistant cells have lower levels of ceramides and hexosylceramides compared to their tamoxifen-sensitive counterpart. Upon perturbing the sphingolipid pathway with small molecule inhibitors of key enzymes, we identified that CERK is essential for tamoxifen-resistant breast cancer cell survival, as well as a fulvestrant-resistant PDxO. CERK inhibition induces ceramide-mediated cell death in tamoxifen-resistant cells. Ceramide-1-phosphate (C1P) partially reverses CERK inhibition-induced cell death in tamoxifen-resistant cells, likely through lowering endogenous ceramide levels. Our findings suggest that ET-resistant breast cancer cells maintain lower ceramide levels as an essential pro-survival mechanism. Consequently, ET-resistant breast cancer models have a unique dependence on CERK as its activity can inhibit de novo ceramide production.

9 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ESEmily Smart
Emily Smart
SSSvetlana E. Semina
Svetlana E. Semina
LALuis H. Alejo
Luis H. Alejo
NKNidhi S. Kansara
Nidhi S. Kansara
JFJonna Frasor
Jonna Frasor
Most metastatic breast cancers arise from estrogen receptor α (ER)-positive disease, and yet the role of ER in promoting metastasis is unclear. Here, we used an ER+ breast cancer cell line that is highly invasive in an ER- and IKKβ-dependent manner. We defined two ER-regulated gene signatures that are specifically regulated in the subpopulations of invasive cells. The first consists of proliferation-associated genes, which is a known function of ER, which actually suppress rather than enhance invasion. The second signature consists of genes involved in essential biological processes, such as organelle assembly and vesicle trafficking. Importantly, the second subpopulation-specific signature is associated with aggressive disease and poor patient outcome, independently of proliferation. These findings indicate a complex interplay between ER-driven proliferation and invasion, and they define new ER-regulated gene signatures that are predictive of aggressive ER+ breast cancer.

7 November 2019 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
OAOlga Andreeva
Olga Andreeva
SSS.E. Semina
S.E. Semina
Alexander ScherbakovAlexander Scherbakov
Alexander Scherbakov
MKM.A. Krasil`nIkov
M.A. Krasil`nIkov
Breast cancer (BC) is found approximately at 1 million of new cases annually, and mortality reaches 400 thousand. Acquired resistance to tamoxifen limits adjuvant therapy`s potential to combat BC. Notably, up to 50% of ER+ BC cases fail to respond tamoxifen therapy. Elucidating molecular mechanisms of tamoxifen resistance development and transfer is important to develop novel therapies. New biomarkers indicating tamoxifen resistance are also to be found for proper development of precise therapies. Previously we have demonstrated the existence of tamoxifen resistance horizontal transfer at least particularly mediated by exosomes. The latter can carry microRNAs cargo. In this work using NGS approaches we investigated the changes of intracellular miRNA content between control cells and cells that acquired resistance to tamoxifen in 3 different ways: a) by prolonged cultivation of cells with tamoxifen (MCF7/T); b) by co-cultivation of MCF7 and MCF7/T (MCF7/R), and c) by cultivation of MCF7 with addition of exosomes derived from MCF7/R (MCF7/exoT). All three routes of tamoxifen resistance acquisition in vitro revealed selective changes in a few miRNA levels. There were 8 such miRNA found in MCF7/T cells (with p-value <0.05), 6 miRNAs in MCF7/R, and 5 miRNAs found in MCF7/exoT. Notably, these overlap in 3 miRNAs: miR-30a-5p, miR-484 and miR-1301-3p. Tamoxifen resistance was accompanied by upregulation of miR-30a-5p (∼ 5,2 fold) and downregulation of both miR-484 and miR-1301-3p (∼4,2 and 6,7 fold respectively). Intriguingly miR-30a-5p was also significantly elevated in the exosomes derived from resistant cells indicating this miRNA`s possible involvement into the resistance transfer. Tamoxifen resistance acquisition in vitro by MCF7 cells have revealed common patterns of changes in 3 miRNAs levels that can represent special biomarkers connected with tamoxifen resistance of breast cancer cells. The authors. Experiments were supported by Russian Science Foundation (17-75-10212 – experiments with tamoxifen-resistant cells; 19-15-00245 – experiments with exosomal miRNAs). All authors have declared no conflicts of interest.

3 April 2023
Verified
Other
Open access
IKIrida Kastrati
Irida Kastrati
SJStacey E. P. Joosten
Stacey E. P. Joosten
SSSvetlana E. Semina
Svetlana E. Semina
LALuis H. Alejo
Luis H. Alejo
SBSvitlana D. Brovkovych
Svitlana D. Brovkovych
JFJonna Frasor
Jonna Frasor
Supplemental Figure 1. Tamoxifen treatment induces expression of NFκBB-related genes. Supplementary Figure 2. Immune cell composition and numbers in the tumor microenvironment do not significantly change upon tamoxifen treatment. Supplementary Figure 3. NFκB pathway and EMT/stemness factors in tamoxifen-tolerant persisters in T47D cells. Supplementary Figure 4. Expression of p65 and p50 proteins in MCF-7 CRISPR/Cas9 knock out clones. Supplementary Figure 5. NFκB pathway is not directly activated by tamoxifen. Supplementary Figure 6. Sorted NFκB+ vs NFκBâ^' or unsorted tamoxifen-tolerant cells based on GFP expression were reseeded for another round of clonogenic assay and the %GFP+ population was quantified in the second round.

3 April 2023
Verified
Other
Open access
IKIrida Kastrati
Irida Kastrati
SJStacey E. P. Joosten
Stacey E. P. Joosten
SSSvetlana E. Semina
Svetlana E. Semina
LALuis H. Alejo
Luis H. Alejo
SBSvitlana D. Brovkovych
Svitlana D. Brovkovych
JFJonna Frasor
Jonna Frasor
Supplemental Materials and Methods and Figure Legends